1. Market Research
  2. > Ceregene, Inc. – Product Pipeline Review – 2013

Ceregene, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Ceregene, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Ceregene, Inc. - Product Pipeline Review - 2013” provides data on the Ceregene, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ceregene, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ceregene, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ceregene, Inc. - Brief Ceregene, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ceregene, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ceregene, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ceregene, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ceregene, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ceregene, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ceregene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ceregene, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ceregene, Inc. and identify potential opportunities in those areas.

Table Of Contents

Ceregene, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Ceregene, Inc. Snapshot 5
Ceregene, Inc. Overview 5
Key Information 5
Key Facts 5
Ceregene, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Ceregene, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Ceregene, Inc. - Pipeline Products Glance 10
Ceregene, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Ceregene, Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Ceregene, Inc. - Drug Profiles 12
CERE-110 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
CERE-120 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
CERE-135 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
CERE-140 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Ceregene, Inc. - Pipeline Products by Route of Administration 19
Ceregene, Inc. - Pipeline Products By Mechanism of Action 20
Ceregene, Inc. - Recent Pipeline Updates 21
Ceregene, Inc. - Dormant Projects 23
Ceregene, Inc. - Locations And Subsidiaries 24
Head Office 24
Ceregene, Inc., Recent Developments 25
Ceregene, Inc.- Press Release 25
Apr 19, 2013: Ceregene Reports Top-line Data From Phase IIb Study Of CERE-120 For Treatment Of Parkinson's Disease 25
Mar 13, 2013: Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment For CERE-110 Phase II Trial 26
Oct 19, 2010: Ceregene Initiates Phase IIb Trial Of CERE-120 For Parkinson's Disease 27
Jun 22, 2010: The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease 28
Apr 28, 2010: Ceregene Initiates New Phase I/II Trial Of CERE-120 For Parkinson's Disease 29
Financial Deals Landscape 31
Ceregene, Inc., Deals Summary 31
Ceregene, Inc., Pharmaceuticals and Healthcare, Deal Details 32
Venture Financing 32
Ceregene Secures US$11.5 Million In Series D Venture Financing 32
Ceregene Secures US$28.1 Million In Series C Financing 34
Partnerships 36
Ceregene Enters Into Agreement With Genzyme 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Ceregene, Inc., Key Information 5
Ceregene, Inc., Key Facts 5
Ceregene, Inc. - Pipeline by Indication, 2013 7
Ceregene, Inc. - Pipeline by Stage of Development, 2013 8
Ceregene, Inc. - Monotherapy Products in Pipeline, 2013 9
Ceregene, Inc. - Phase II, 2013 10
Ceregene, Inc. - Pre-Clinical, 2013 11
Ceregene, Inc. - Pipeline By Route of Administration, 2013 19
Ceregene, Inc. - Pipeline Products By Mechanism of Action, 2013 20
Ceregene, Inc. - Recent Pipeline Updates, 2013 21
Ceregene, Inc. - Dormant Developmental Projects,2013 23
Ceregene, Inc., Deals Summary 31
Ceregene Secures US$11.5 Million In Series D Venture Financing 32
Ceregene Secures US$28.1 Million In Series C Financing 34
Ceregene Enters Into Agreement With Genzyme 36



List of Figures

Ceregene, Inc. - Pipeline by Indication, 2013 7
Ceregene, Inc. - Pipeline by Stage of Development, 2013 8
Ceregene, Inc. - Monotherapy Products in Pipeline, 2013 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.